# Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial

> **NCT07281508** · PHASE3 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 100 (estimated)

## Conditions studied

- Cisplatin-related Hearing Loss

## Interventions

- **DRUG:** Transtympanic sodium thiosulphate (STS) 0.1M/0,5% hyaluronate

## Key facts

- **NCT ID:** NCT07281508
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-14
- **Primary completion:** 2030-03-23
- **Final completion:** 2030-03-23
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281508, "Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07281508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*